Reardon M A, Weber G
Cancer Res. 1986 Jul;46(7):3673-6.
Carbamoyl-phosphate synthase II (glutamine-hydrolyzing) (EC 6.3.5.5) (synthase II) is the first and rate-limiting enzyme in the de novo UTP biosynthetic pathway. Leucine pulse-labeling in the rat demonstrated that in the rapidly proliferating hepatoma 3924A the ratio of radioactivity of synthase II to that of total cytosolic protein was 168.2 +/- 11.0 (SE) X 10(-3). This synthetic rate for the tumor enzyme was 9.7-fold higher than that for the liver synthase II, 17.4 +/- 4.0 X 10(-3). Since the degradation rate for hepatoma 3924A enzyme (t1/2 = 65.5 h) was similar to the rate for liver synthase II (t1/2 = 69.3 h), the increase in tumor synthase II activity and amount was due primarily to an elevation in enzyme synthesis in the presence of an unaltered catabolic rate. The results indicate that the reprogramming of gene expression in the hepatoma entails an increased production rate of the rate-limiting enzyme of UTP synthesis. This increase in the activity, concentration, and synthesis of tumor synthase II should provide a heightened capacity for the de novo pyrimidine biosynthetic pathway, thus conferring a selective advantage to the cancer cells.
氨甲酰磷酸合成酶II(谷氨酰胺水解)(EC 6.3.5.5)(合成酶II)是从头合成UTP生物合成途径中的首个限速酶。对大鼠进行亮氨酸脉冲标记显示,在快速增殖的肝癌3924A中,合成酶II的放射性与总胞质蛋白放射性的比值为168.2±11.0(SE)×10⁻³。肿瘤酶的合成速率比肝脏合成酶II的合成速率高9.7倍,肝脏合成酶II的合成速率为17.4±4.0×10⁻³。由于肝癌3924A酶的降解速率(t1/2 = 65.5小时)与肝脏合成酶II的降解速率(t1/2 = 69.3小时)相似,肿瘤合成酶II活性和含量的增加主要是由于在分解代谢速率不变的情况下酶合成增加。结果表明,肝癌中基因表达的重编程导致UTP合成限速酶的生产率提高。肿瘤合成酶II活性、浓度和合成的这种增加应会提高从头嘧啶生物合成途径的能力,从而赋予癌细胞选择性优势。